Results 1 to 10 of about 2,658 (154)

Chinese Clinical Named Entity Recognition with ALBERT and MHA Mechanism

open access: yesEvidence-Based Complementary and Alternative Medicine, Volume 2022, Issue 1, 2022., 2022
Traditional clinical named entity recognition methods fail to balance the effectiveness of feature extraction of unstructured text and the complexity of neural network models. We propose a model based on ALBERT and a multihead attention (MHA) mechanism to solve this problem.
Dongmei Li   +4 more
wiley   +1 more source

Chinese Medical Entity Recognition Model Based on Character and Word Vector Fusion

open access: yesScientific Programming, Volume 2021, Issue 1, 2021., 2021
The medical information carried in electronic medical records has high clinical research value, and medical named entity recognition is the key to extracting valuable information from large‐scale medical texts. At present, most of the studies on Chinese medical named entity recognition are based on character vector model or word vector model.
Qinghui Zhang   +5 more
wiley   +1 more source

MMC celebrating 6 years of experience and expansion 庆祝MMC六年的经验和壮大

open access: yes, 2022
Journal of Diabetes, Volume 14, Issue 5, Page 356-357, May 2022.
Itamar Raz
wiley   +1 more source

Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022 [PDF]

open access: yes, 2023
Renal cell carcinoma (RCC) is one of the three major urinary system tumors. With the changes of lifestyle and the rise of obesity, hypertension and other diseases, the incidence of RCC is increasing.
TIAN Xi, XU Wenhao, ZHU Shuxuan, AIHETAIMUJIANG•Anwaier, SU Jiaqi, YE Shiqi, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei
core   +1 more source

Review of the Role of EBUS-TBNA for the Pulmonologist, Including Lung Cancer Staging [PDF]

open access: yes, 2010
This review focuses on the role of endobronchial ultrasound-guided transbronchial needle aspiration in day-to-day pulmonology practice. Case examples are given of the common indications for endobronchial ultrasound-guided transbronchial needle aspiration
Alan HODGSON   +4 more
core   +1 more source

双膦酸盐类药物用于肿瘤辅助治疗的临床研究进展 [PDF]

open access: yes, 2018
双膦酸盐是用于骨骼疾病及钙代谢性疾病治疗的一类药物,主要用于治疗骨质疏松症、佩吉特病、高钙血症等。同时临床研究显示双膦酸盐还可用于多发性骨髓瘤、乳腺癌、肾癌、前列腺癌等疾病的辅助治疗,改善患者的临床结局,尤其是唑来膦酸盐的抗肿瘤效果更具优势,被广泛应用于多种恶性肿瘤的临床研究。本文就双膦酸盐在肿瘤辅助治疗中的临床研究进展进行综述。国家自然科学基金面上项目 ...
何斌   +4 more
core   +1 more source

Pre‐existing type 2 diabetes is an adverse prognostic factor in patients with renal cell carcinoma 2型糖尿病是肾细胞癌患者的不良预后因素

open access: yesJournal of Diabetes, Volume 11, Issue 12, Page 993-1001, December 2019., 2019
Highlights Type 2 diabetes (T2D) is an independent predictor of survival and recurrence after surgery in patients with renal cell carcinoma (RCC). This finding reveals the importance of T2D in determining the prognosis of patients with RCC. Abstract Background Diabetes is a risk factor for various cancers, but its prognostic role in renal cell ...
Haosen Yang   +8 more
wiley   +1 more source

Effect of lysine demethylase 5C on renal carcinoma metastasis [PDF]

open access: yes, 2023
Objective·To investigate the effects of lysine demethylase 5C (KDM5C) on the migration and invasion of renal clear cell carcinoma, analyze the genes regulated by KDM5C and explore the mechanisms of promoting renal cell carcinoma after its inactivation ...
CHEN Ningdai   +4 more
core   +1 more source

PDIA3在肾癌中的表达变化及临床意义

open access: yesZhongguo shiyan zhenduanxue, 2021
肾细胞癌又名肾癌,约占肾脏恶性疾病的80%-90%,是泌尿系统中发病率仅次于前列腺癌、膀胱癌的恶性肿瘤[1]。肾癌的早期临床症状较为隐匿,发病原因尚未明确[2]。因此寻找到新的生物学标志物对肾癌的诊断、治疗及预后都尤为重要[3]。本文探讨了蛋白质二硫键异构酶A3(PDIA3)在肾癌组织中的表达量,以验证其是否可以成为诊断肾癌的新候选标志物。
杨旭, 崔璨璨, 杨照微, 徐飞
doaj  

Characteristics of Cancer Epidemiology among 0-14 years old Chinese Children,2005—2015 [PDF]

open access: yes, 2022
BackgroundCancer has become a leading cause of death for Chinese children, imposing a great economic burden on society and families. Therefore, it is extremely important to understand the epidemicsizes and trends of childhood malignancies.ObjectiveTo ...
TANG Hui, GUO Hong, CAO Fang, YAN Yizhong, HE Jia, GUO Heng, CUI Xiaobin, HU Yunhua
core   +1 more source

Home - About - Disclaimer - Privacy